Sulodexide Treatment in Patients With Dense Deposit Disease

Withdrawn before enrolling · Phase 1

Conditions studied: Dense Deposit Disease

In brief

The purpose of this study is to see if a medicine called Sulodexide will help prevent or slow down the progression of Membranoproliferative Glomerulonephritis type II/Dense Deposit Disease. Sulodexide is not yet FDA approved and has not been studied in children. Study aim/hypotheses: to measure the efficacy of Sulodexide treatment in patients with the above disease/s.

Key facts

Study ID
NCT00583427
Run by
University of Iowa
People needed
0
Starts
2007-12-01
Expected to finish
2009-12-01
Last updated by the study team
2015-06-11

Who can join

Age: 5 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.